INNOSTAR ORD A (SHH) EQSW Exp:
Shanghai InnoStar Bio-tech Co., Ltd. provides drug research and development services in China and internationally. The company offers screening and discovery, nonclinical assessment stage, and clinical development stage services in the areas of chemical products, biologics, cell and gene therapeutics, radiopharmaceuticals, and traditional Chinese medicines. The company was founded in 2010 and is … Read more
INNOSTAR ORD A (SHH) EQSW Exp: (688710) - Net Assets
Latest net assets as of June 2025: CN¥2.36 Billion CNY
Based on the latest financial reports, INNOSTAR ORD A (SHH) EQSW Exp: (688710) has net assets worth CN¥2.36 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.21 Billion) and total liabilities (CN¥849.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.36 Billion |
| % of Total Assets | 73.57% |
| Annual Growth Rate | 47.1% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 31.7 |
INNOSTAR ORD A (SHH) EQSW Exp: - Net Assets Trend (2021–2024)
This chart illustrates how INNOSTAR ORD A (SHH) EQSW Exp:'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for INNOSTAR ORD A (SHH) EQSW Exp: (2021–2024)
The table below shows the annual net assets of INNOSTAR ORD A (SHH) EQSW Exp: from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.40 Billion | +46.52% |
| 2023-12-31 | CN¥1.64 Billion | +13.73% |
| 2022-12-31 | CN¥1.44 Billion | +91.09% |
| 2021-12-31 | CN¥754.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to INNOSTAR ORD A (SHH) EQSW Exp:'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 423.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥528.71 Million | 22.10% |
| Other Components | CN¥1.86 Billion | 77.90% |
| Total Equity | CN¥2.39 Billion | 100.00% |
INNOSTAR ORD A (SHH) EQSW Exp: Competitors by Market Cap
The table below lists competitors of INNOSTAR ORD A (SHH) EQSW Exp: ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Departure Bay Capital Corp.
V:DBC-P
|
$77.36K |
|
PETROBRAS (PJXC.SG)
STU:PJXC
|
$77.38K |
|
DAIWA SEC GRP - Dusseldorf Stock Exchang
DU:DSE
|
$77.41K |
|
Applied Nutrition Plc
LSE:APN
|
$77.41K |
|
TOKYU CONSTRUCTION
MU:TCW
|
$77.24K |
|
ArthaLand Corp Preferred Series D
PSE:ALCPD
|
$77.23K |
|
KwikClick Inc
PINK:KWIK
|
$77.22K |
|
Trustpilot Group PLC
LSE:TRST
|
$77.09K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INNOSTAR ORD A (SHH) EQSW Exp:'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,618,070,569 to 2,391,927,683, a change of 773,857,114 (47.8%).
- Net income of 147,775,836 contributed positively to equity growth.
- Dividend payments of 228,000 reduced retained earnings.
- Other factors increased equity by 626,309,277.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥147.78 Million | +6.18% |
| Dividends Paid | CN¥228.00K | -0.01% |
| Other Changes | CN¥626.31 Million | +26.18% |
| Total Change | CN¥- | 47.83% |
Book Value vs Market Value Analysis
This analysis compares INNOSTAR ORD A (SHH) EQSW Exp:'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.39x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 7.20x to 3.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | CN¥8.00 | CN¥57.59 | x |
| 2022-12-31 | CN¥13.31 | CN¥57.59 | x |
| 2023-12-31 | CN¥15.30 | CN¥57.59 | x |
| 2024-12-31 | CN¥16.97 | CN¥57.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently INNOSTAR ORD A (SHH) EQSW Exp: utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.18%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.94%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.35x
- Recent ROE (6.18%) is below the historical average (10.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 12.44% | 14.91% | 0.32x | 2.59x | CN¥17.03 Million |
| 2022 | 9.62% | 15.69% | 0.33x | 1.86x | CN¥-5.32 Million |
| 2023 | 12.02% | 18.72% | 0.37x | 1.72x | CN¥32.64 Million |
| 2024 | 6.18% | 12.94% | 0.35x | 1.35x | CN¥-91.42 Million |
Industry Comparison
This section compares INNOSTAR ORD A (SHH) EQSW Exp:'s net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $1,443,093,618
- Average return on equity (ROE) among peers: -7.88%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INNOSTAR ORD A (SHH) EQSW Exp: (688710) | CN¥2.36 Billion | 12.44% | 0.36x | $77.24K |
| Zhejiang Int'L Group Co Ltd (000411) | $177.19 Million | 13.55% | 0.63x | $201.14 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $280.61 Million | 7.70% | 0.99x | $310.45 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $638.18 Million | -181.03% | 3.22x | $202.85 Million |
| Hubei Guangji Pharmaceutical Co Ltd (000952) | $477.68 Million | 3.28% | 0.64x | $234.89 Million |
| Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) | $361.29 Million | 26.02% | 0.32x | $146.91 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $9.15 Billion | 2.09% | 0.37x | $1.03 Billion |
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | $278.08 Million | 2.72% | 0.13x | $459.10 Million |
| Chongqing Lummy Pharmaceutical (300006) | $107.91 Million | 22.70% | 0.99x | $476.38 Million |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $1.44 Billion | 5.91% | 0.29x | $1.19 Billion |
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | $1.53 Billion | 18.22% | 0.05x | $893.48 Million |